1,721,248 research outputs found
Duration of anticoagulation and risk of recurrent thromboembolism in carriers of factor V Leiden or prothrombin mutation
No full textJ Thromb Haemost. 2008 Dec;6(12):2223-4. Epub 2008 Oct 1.
Duration of anticoagulation and risk of recurrent thromboembolism in carriers of
factor V Leiden or prothrombin mutation.
Prandoni P, Tormene D, Spiezia L, Pesavento R, Simioni P.
Comment in
J Thromb Haemost. 2008 Dec;6(12):2225-6.
PMID: 18983490 [PubMed - indexed for MEDLINE
Idraparinux: review of its clinical efficacy and safety for prevention andtreatment of thromboembolic disorders.
No full text1. Expert Opin Investig Drugs. 2008 May;17(5):773-7.
Idraparinux: review of its clinical efficacy and safety for prevention and
treatment of thromboembolic disorders.
Prandoni P, Tormene D, Perlati M, Brandolin B, Spiezia L.
Department of Medical and Surgical Sciences, Thromboembolism Unit, University of
Padua, 35128 - Padua, Italy. [email protected]
BACKGROUND: Idraparinux is a synthetic pentasaccharide that binds to antithrombin
with high affinity. In view of its long half-life, it is suitable for once-a-week
administration.
OBJECTIVE: To review the evidence favoring the use of idraparinux for the acute
and long-term treatment of patients with venous thromboembolism (VTE) and for the
prevention of thromboembolic events in patients with atrial fibrillation (AF).
METHODS: All preclinical and clinical studies carried out with the use of
idraparinux were sought through electronic searches of MEDLINE from January 1,
1999 up to December 31, 2007.
RESULTS: The administration of idraparinux in subcutaneous fixed doses of 2.5 mg
once weekly was found to be as effective and safe as conventional antithrombotic
therapy in the initial treatment of patients with deep vein thrombosis, but less
effective than standard therapy in the initial treatment of patients with primary
pulmonary embolism. During a 6-month extension of thromboprophylaxis, idraparinux
was effective in preventing recurrent VTE but was associated with an increased
risk of bleeding versus placebo. Finally, in patients with AF the long-term
treatment with idraparinux was as effective as vitamin K antagonists, but caused
more bleeding.
CONCLUSIONS: In its current formulation, idraparinux can be recommended only for
the initial treatment of patients with deep vein thrombosis. The bioequipotency
of a biotinylated version of idraparinux (idrabiotaparinux), whose effects can be
reversed by a neutralizing agent (avidin), is under investigation in the
treatment of VTE at present, as is the use of lower doses in patients with AF.
PMID: 18447601 [PubMed - indexed for MEDLINE
Predictive value of D-Dimer test, persistent residual venous thromnbosis, and thrombophilia for venous thromboembolism recurrence
No full text
Erratum: The impact of disseminated intravascular coagulation on the outcome of cancer patients with venous thromboembolism (Blood Coagulation and Fibrinolysis (2015) 26 (709-711))
No full textAntithrombin type I deficiency in a young nigerian man with recurrent venous thrombosis: molecular characterization of a new frameshift mutation leading to a stop codon
No full text- …
